Amicus Therapeutics Inc. (FOLD)
Amicus Therapeutics Statistics
Share Statistics
Amicus Therapeutics has 307.24M shares outstanding. The number of shares has increased by 1.16% in one year.
| Shares Outstanding | 307.24M |
| Shares Change (YoY) | 1.16% |
| Shares Change (QoQ) | 0.75% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 296.87M |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 18.23M, so 6.1% of the outstanding shares have been sold short.
| Short Interest | 18.23M |
| Short % of Shares Out | 6.1% |
| Short % of Float | 6.28% |
| Short Ratio (days to cover) | 7.91 |
Valuation Ratios
The PE ratio is -51.1 and the forward PE ratio is 25.41. Amicus Therapeutics's PEG ratio is 0.79.
| PE Ratio | -51.1 |
| Forward PE | 25.41 |
| PS Ratio | 5.43 |
| Forward PS | 1.9 |
| PB Ratio | 14.78 |
| P/FCF Ratio | -76.57 |
| PEG Ratio | 0.79 |
Enterprise Valuation
Amicus Therapeutics Inc. has an Enterprise Value (EV) of 4.39B.
| EV / Earnings | -78.18 |
| EV / Sales | 8.3 |
| EV / EBITDA | 149.25 |
| EV / EBIT | 176.33 |
| EV / FCF | -117.15 |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 2.29.
| Current Ratio | 3.39 |
| Quick Ratio | 2.6 |
| Debt / Equity | 2.29 |
| Total Debt / Capitalization | 69.57 |
| Cash Flow / Debt | -0.08 |
| Interest Coverage | 0.5 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is 7.61%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | 7.61% |
| Revenue Per Employee | $1,058,707.41 |
| Profits Per Employee | $-112,436.87 |
| Employee Count | 499 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 0.45 |
Taxes
| Income Tax | 27.35M |
| Effective Tax Rate | -0.95 |
Stock Price Statistics
The stock price has increased by -28.61% in the last 52 weeks. The beta is 0.69, so Amicus Therapeutics's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | -28.61% |
| 50-Day Moving Average | 9.27 |
| 200-Day Moving Average | 10.2 |
| Relative Strength Index (RSI) | 35.37 |
| Average Volume (20 Days) | 2.35M |
Income Statement
In the last 12 months, Amicus Therapeutics had revenue of 528.29M and earned -56.11M in profits. Earnings per share was -0.18.
| Revenue | 528.29M |
| Gross Profit | 475.35M |
| Operating Income | 24.88M |
| Net Income | -56.11M |
| EBITDA | 29.39M |
| EBIT | 24.88M |
| Earnings Per Share (EPS) | -0.18 |
Balance Sheet
The company has 213.75M in cash and 443.64M in debt, giving a net cash position of -229.89M.
| Cash & Cash Equivalents | 213.75M |
| Total Debt | 443.64M |
| Net Cash | -229.89M |
| Retained Earnings | -2.74B |
| Total Assets | 785.03M |
| Working Capital | 356.03M |
Cash Flow
In the last 12 months, operating cash flow was -33.89M and capital expenditures -3.55M, giving a free cash flow of -37.44M.
| Operating Cash Flow | -33.89M |
| Capital Expenditures | -3.55M |
| Free Cash Flow | -37.44M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 89.98%, with operating and profit margins of 4.71% and -10.62%.
| Gross Margin | 89.98% |
| Operating Margin | 4.71% |
| Pretax Margin | -5.44% |
| Profit Margin | -10.62% |
| EBITDA Margin | 5.56% |
| EBIT Margin | 4.71% |
| FCF Margin | -7.09% |
Dividends & Yields
FOLD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.14% |
| FCF Yield | -1.45% |
Analyst Forecast
The average price target for FOLD is $17, which is 102.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 102.1% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -0.9 |
| Piotroski F-Score | 4 |